Zeta CD123 Antibody. Zeta’s mouse recombinant antibody recognizes CD123. Human CD123, the 70 kd IL-3 receptor α chain (IL-3Rα), is associated with the 120-140 kd β subunit. The β chain of CD123 is shared with the receptors for interleukins IL-5 and GM-CSF. IL-3Rα is expressed on hematopoietic progenitors and plays an important role in hematopoietic progenitor cell growth and differentiation. Zeta’s monoclonal antibody to CD123 has been reported to block the binding of 125I-IL-3 to high and low affinity IL-3 receptors. In functional experiments, Zeta’s antibody to CD123 was found to inhibit acute myeloid leukemia cell proliferation, basophil histamine release, endothelial cell-mediated IL-8 secretion, and neutrophil transmigration.
Zeta’s monoclonal antibody to CD123 reacts with plasmacytoid dendritic cells (PDC). PDC play a crucial role in the initiation of antiviral and antitumoral immune responses and produce type I interferons a and b. The Zeta CD123 antibody is useful in diagnosis of Kikuchi disease, hyaline vascular type of Castleman disease, lupus, and primary cutaneous marginal zone B-cell lymphoma.
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.